The Swiss pharmaceutical giant's plant will produce compounds needed for radioligand therapy (RLT), a form of precision ...

Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make ...

Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet ...

The facility is part of the company’s commitment, earlier this year, to invest $23 billion in the U.S. over the next five ...

Novartis, a global innovative medicines company, has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, CA.

Novartis plans to acquire Avidity Biosciences to add RNA therapeutics to its neuroscience biz to target rare genetic ...

Novartis invests $23B in U.S. infrastructure, opening a new Carlsbad facility and expanding radioligand therapy sites. Read ...

Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Novartis AG is nearing a deal to buy biotechnology company Avidity Biosciences Inc., according to a person familiar with the matter.

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter, dragging the Swiss company's shares lower, as its top-selling drug comes under pressure from cheaper ...